Sickle cell disease (SCD) is the most common inherited blood cell disorder in the U.S., according to the American Society of Hematology. Bone marrow transplant (BMT), or allogeneic hematopoietic stem cell transplant, is considered the only potentially curative therapy for SCD. Although a matched sibling donor transplant is now the standard of care, it is not always considered at the outset when treating patients with SCD.
Instead, many patients with SCD receive disease-modifying therapies. In many cases, a patient’s SCD is treated as a chronic illness until the symptoms become too severe to manage therapeutically. It is at that time that a typical patient first hears of the potentially curative properties of BMT.
Please read detailed news about Multidisciplinary sickle cell program includes curative bone marrow transplant at: https://www.mayoclinic.org/medical-professionals/cancer/news/multidisciplinary-sickle-cell-program-including-curative-bone-marrow-transplant/mac-20525836/?vp=mpg-20426270